Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials (Q38386497)

2 September 2017

1 reference

title

Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials (English)

1 reference

2 September 2017

0 references

1 reference

M E Lynch

1

1 reference

PubMed ID

25796592

2 September 2017

Mark A Ware

series ordinal

2

1 reference

2 September 2017

22 March 2015

1 reference

Journal of Neuroimmune Pharmacology

2 September 2017

1 reference

2 September 2017

10

1 reference

2 September 2017

2

1 reference

2 September 2017

293-301

1 reference

https://scigraph.springernature.com/pub.10.1007/s11481-015-9600-6

2 September 2017

0 references

cites work

Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

The evidence for pharmacological treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

The pharmacotherapy of chronic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

The need for a Canadian pain strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Chronic pain in Canada--prevalence, treatment, impact and the role of opioid analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Endocannabinoids in nervous system health and disease: the big picture in a nutshell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Cannabis use for chronic non-cancer pain: results of a prospective survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Low-dose vaporized cannabis significantly improves neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9600-6

Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations

21 January 2018

1 reference

12 December 2020

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

12 December 2020

Chronic pain in Australia: a prevalence study

1 reference

12 December 2020

Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial

1 reference

12 December 2020

10.1007/S11481-015-9600-6

Identifiers

DOI

1 reference

PubMed ID

25796592

Dimensions Publication ID

2 September 2017

0 references

1 reference

PubMed ID

25796592